Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

BA-BE Studies: SOP for Audit Trail Review in Bioanalytical Software – V 2.0

Posted on By

BA-BE Studies: SOP for Audit Trail Review in Bioanalytical Software – V 2.0

Standard Operating Procedure for Audit Trail Review in Bioanalytical Software for BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/188/2025
Supersedes SOP/BA-BE/188/2022
Page No. Page 1 of 10
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define a consistent and compliant process for reviewing audit trails in bioanalytical software systems to ensure transparency, traceability, and integrity of data generated during BA/BE studies.

2. Scope

This SOP applies to all computerized systems used in the bioanalytical lab that generate, store, or process data associated with BA/BE studies, such as Chromatography Data Systems (CDS), Laboratory

Information Management Systems (LIMS), and Instrument Operating Software.

3. Responsibilities

  • Analyst: Ensures accurate data entry and documents actions during method runs.
  • QA Officer: Performs independent audit trail reviews at predefined intervals and prior to critical report sign-offs.
  • System Administrator: Maintains audit trail settings and access control to ensure audit trails cannot be disabled or altered.
  • Department Head: Ensures audit trail review timelines are adhered to.
See also  BA-BE Studies: SOP for Clinical Documentation of Adverse Events - V 2.0

4. Accountability

The Head of Bioanalytical Department is accountable for ensuring that audit trail reviews are conducted as per this SOP to uphold compliance with 21 CFR Part 11 and related data integrity requirements.

5. Procedure

5.1 Audit Trail Configuration

  1. System Administrators must ensure audit trail features are enabled and validated in all analytical software used.
  2. Audit trails must capture:
    • User ID, date/time of action
    • Original value and changed value
    • Reason for change (if applicable)
  3. Audit trail records shall be time-stamped and stored securely with no overwrite permission.

5.2 Audit Trail Review Triggers

  1. Audit trail reviews must be conducted at the following stages:
    • After completion of each analytical run
    • Before final study report submission
    • During system qualification or method validation
  2. Document each review in Annexure-1: Audit Trail Review Log.

5.3 Review Activities

  1. Open audit trail viewer and filter log entries based on:
    • Run ID or batch ID
    • Date range
    • Actions such as deletion, reintegration, manual edits
  2. Review critical parameters:
    • Manual integrations
    • Changes to sample identifiers
    • System errors or unauthorized access attempts
  3. If abnormal or suspicious entries are detected:
    • Raise a deviation form
    • Initiate a root cause analysis and CAPA
    • Escalate to QA and document in Annexure-2: Audit Trail Deviation Report
See also  BA-BE Studies: SOP for Clinical Trial Photography and Video Recording - V 2.0

5.4 Documentation and Archiving

  1. Attach audit trail printouts or PDF exports to the batch documentation for traceability.
  2. Maintain electronic records in secure archives for a minimum of 5 years.
  3. Restrict audit trail access to authorized reviewers only.

5.5 Periodic QA Review

  1. QA shall perform periodic (monthly or quarterly) audit trail reviews independent of ongoing study reviews.
  2. Summarize observations in Annexure-3: Periodic Audit Trail Summary and share with department head.

6. Abbreviations

  • BA/BE: Bioavailability/Bioequivalence
  • CDS: Chromatography Data System
  • LIMS: Laboratory Information Management System
  • CAPA: Corrective and Preventive Action
  • QA: Quality Assurance
  • SOP: Standard Operating Procedure

7. Documents

  1. Audit Trail Review Log – Annexure-1
  2. Audit Trail Deviation Report – Annexure-2
  3. Periodic Audit Trail Summary – Annexure-3

8. References

  • 21 CFR Part 11 – Electronic Records; Electronic Signatures
  • MHRA GXP Data Integrity Guidance
  • WHO TRS No. 996 – Guidance on Good Data and Record Management
  • ICH Q7 – Good Manufacturing Practice for Active Pharmaceutical Ingredients
See also  BA-BE Studies: SOP for Post-Dosing Restrictions and Observations - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Audit Trail Review Log

Date System Run ID Reviewer Observations Status
16/04/2025 Empower 3 BAE-097 Sunita Reddy No discrepancies Closed

Annexure-2: Audit Trail Deviation Report

Deviation ID Observed By Action Description Date/Time CAPA Status
AT-2025-03 QA Officer Manual reintegration without reason 15/04/2025 10:12 Training and procedure update Closed

Annexure-3: Periodic Audit Trail Summary

Review Period System Total Entries Reviewed Observations Reviewed By Date
Q1 2025 Waters Empower 125 No critical findings QA Team 10/04/2025

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial Release New SOP QA Head
17/04/2025 2.0 Added system configuration and periodic review annexures Audit Feedback QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Sterile Injectable Manufacturing: SOP for Operation of Filling Machines for Injections – V 2.0
Next Post: Analytical Method Development: Zeta Potential Determination SOP – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2026 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version